ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
Dow Jones
39.118,86
-0,12%
Euro vs US Dollar
1,07505
0,14%
Bitcoin
63.326,13
1,05%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Turnstone Biologics Corporation (TSBX)

  7. Turnstone Biologics Corporation (TSBX) News

TSBX

Turnstone Biologics (TSBX)

Turnstone Biologics Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TSBX
DatumZeitQuelleÜberschriftSymbolFirma
05/06/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSBXTurnstone Biologics Corporation
31/05/202422h23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TSBXTurnstone Biologics Corporation
13/05/202423h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TSBXTurnstone Biologics Corporation
13/05/202423h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSBXTurnstone Biologics Corporation
13/05/202423h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSBXTurnstone Biologics Corporation
13/05/202423h01GlobeNewswire Inc.Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsNASDAQ:TSBXTurnstone Biologics Corporation
08/05/202415h00GlobeNewswire Inc.Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care ConferenceNASDAQ:TSBXTurnstone Biologics Corporation
16/04/202415h00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:TSBXTurnstone Biologics Corporation
21/03/202422h06GlobeNewswire Inc.Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business HighlightsNASDAQ:TSBXTurnstone Biologics Corporation
05/03/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSBXTurnstone Biologics Corporation
21/02/202412h00GlobeNewswire Inc.Turnstone Biologics to Participate in Upcoming Investor ConferencesNASDAQ:TSBXTurnstone Biologics Corporation
20/02/202423h00GlobeNewswire Inc.Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.NASDAQ:TSBXTurnstone Biologics Corporation
27/11/202312h00GlobeNewswire Inc.Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:TSBXTurnstone Biologics Corporation
10/11/202303h49GlobeNewswire Inc.Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business HighlightsNASDAQ:TSBXTurnstone Biologics Corporation
03/11/202311h00GlobeNewswire Inc.Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:TSBXTurnstone Biologics Corporation
30/10/202311h00GlobeNewswire Inc.Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. WeberNASDAQ:TSBXTurnstone Biologics Corporation
18/10/202300h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSBXTurnstone Biologics Corporation
18/10/202300h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSBXTurnstone Biologics Corporation
18/10/202300h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSBXTurnstone Biologics Corporation
18/10/202300h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSBXTurnstone Biologics Corporation
18/10/202300h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSBXTurnstone Biologics Corporation
18/10/202300h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSBXTurnstone Biologics Corporation
28/09/202312h00GlobeNewswire Inc.Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:TSBXTurnstone Biologics Corporation
01/09/202323h57GlobeNewswire Inc.Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:TSBXTurnstone Biologics Corporation
01/09/202322h39Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSBXTurnstone Biologics Corporation
21/07/202308h15GlobeNewswire Inc.Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public OfferingNASDAQ:TSBXTurnstone Biologics Corporation
 Showing the most relevant articles for your search:NASDAQ:TSBX

Kürzlich von Ihnen besucht

AMEX
SPY
SPDR S&P 500
NYSE
DIS
Walt Disney
NASDAQ
GOOGL
Alphabet
FX
EURUSD
Euro vs US Dollar
TG
LHA
Deutsche Lufthansa
NASDAQ
MSFT
Microsoft
NYSE
MCD
McDonalds
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MRK
Merck
TG
432
Arbor Metals
AMEX
XLF
Financial Select Sector
DBI
SDXP
SDAX
NASDAQ
AAPL
Apple
USOTC
BASFY
BASF (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten